.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,879,706

« Back to Dashboard
Patent 5,879,706 protects VALTREX and is included in one NDA.

Protection for VALTREX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in forty countries.

Summary for Patent: 5,879,706

Title: Valaciclovir tablets containing colloidal silicon dioxide
Abstract:A tablet comprising at least 50% w/w valaciclovir and 0.05 to 3% w/w colloidal silicon dioxide in which the valaciclovir is present within granules of the tablets and the silicon dioxide, a lubricant and a microcrystalline cellulose filler are present extragranularly has excellent hardness and friability properties while still maintaining lubrication of the tablet granules.
Inventor(s): Carter; Barry Howard (Kinston, NC), Tillman; Lloyd Gary (Carlsbad, CA)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:08/875,172
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Process; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 6th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-002Jun 23, 1995RXYes5,879,706*PED► subscribeY
Glaxosmithkline
VALTREX
valacyclovir hydrochloride
TABLET;ORAL020487-001Jun 23, 1995RXNo5,879,706*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,879,706

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9501127Jan 20, 1995
PCT Information
PCT FiledJanuary 19, 1996PCT Application Number:PCT/GB96/00111
PCT Publication Date:July 25, 1996PCT Publication Number: WO96/22082

International Patent Family for Patent: 5,879,706

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)666► subscribe
African Regional IP Organization (ARIPO)9701057► subscribe
Austria190483► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc